Evidence map›Paper›PMID 27714642›Full record

ReviewCurrent atherosclerosis reports2016

Role of New Antiplatelet Drugs on Cardiovascular Disease: Update on Cangrelor.

Ana Lucrecia Marcano, José Luis Ferreiro

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current atherosclerosis reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Ana Lucrecia MarcanoHeart Diseases Institute, Bellvitge University Hospital-IDIBELL, University of Barcelona, c/Feixa Llarga s/n, CP 08907, L'Hospitalet de Llobregat, Barcelona, Spain.
José Luis FerreiroHeart Diseases Institute, Bellvitge University Hospital-IDIBELL, University of Barcelona, c/Feixa Llarga s/n, CP 08907, L'Hospitalet de Llobregat, Barcelona, Spain. jlferreiro@bellvitgehospital.cat.
Bellvitge University Hospital · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dual therapy with a P2Y

Indexed as

Adenosine MonophosphateAnimalsCardiovascular DiseasesHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Adenosine MonophosphatecangrelorPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsReceptors, Purinergic P2Y12Acute coronary syndromeAntiplatelet therapyCangrelorPercutaneous coronary intervention

Identifiers

PMID27714642
OpenAlexW2528887982

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.